<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Establishment Labs Holdings Inc. Jefferies London Healthcare Conference 2025 Transcript</td><td># ì—ìŠ¤íƒ€ë¸”ë¦¬ì‹œë¨¼íŠ¸ ë©ìŠ¤ í™€ë”©ìŠ¤ ì œí¼ë¦¬ìŠ¤ ëŸ°ë˜ í—¬ìŠ¤ì¼€ì–´ ì»¨í¼ëŸ°ìŠ¤ 2025 ë°œí‘œë¬¸<br><br>**ë°œí‘œ ì¼ì:** 2025ë…„<br><br>**íšŒì‚¬:** Establishment Labs Holdings Inc. (NASDAQ: ESTA)<br><br>**ì»¨í¼ëŸ°ìŠ¤:** Jefferies London Healthcare Conference<br><br>---<br><br>**ë°œí‘œì:**<br><br>* íšŒì‚¬ ê²½ì˜ì§„ (ì´ë¦„ ë¯¸ìƒ)<br><br>---<br><br>**ë¶„ì„ê°€:**<br><br>* ì œí¼ë¦¬ìŠ¤ ì• ë„ë¦¬ìŠ¤íŠ¸<br><br>---<br><br>## ë°œí‘œ ë‚´ìš©<br><br>[ë°œí‘œë¬¸ ë‚´ìš©ì´ ì œê³µë˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤]<br><br>---<br><br>**ì°¸ê³ ì‚¬í•­:**<br><br>ë³¸ ë²ˆì—­ë¬¸ì€ íˆ¬ì ì°¸ê³ ìš©ìœ¼ë¡œë§Œ ì œê³µë˜ë©°, íˆ¬ì ê²°ì • ì‹œ ì›ë¬¸ì„ ë°˜ë“œì‹œ í™•ì¸í•˜ì‹œê¸° ë°”ëë‹ˆë‹¤. ì¬ë¬´ ìš©ì–´ ë° ìˆ˜ì¹˜ëŠ” ì›ë¬¸ ê·¸ëŒ€ë¡œ ìœ ì§€í•˜ì˜€ìŠµë‹ˆë‹¤.<br><br>---<br><br>*ë²ˆì—­ ì™„ë£Œ*<br><br>**ì¶”ê°€ ì •ë³´ê°€ í•„ìš”í•˜ì‹  ê²½ìš°, ì‹¤ì œ ë°œí‘œ ë‚´ìš©ì´ í¬í•¨ëœ ì „ì²´ transcriptë¥¼ ì œê³µí•´ ì£¼ì‹œë©´ ì •í™•í•œ ë²ˆì—­ì„ ì œê³µí•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤.*</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Establishment Labs Holdings Inc. - Jefferies London Healthcare Conference 2025 ìš”ì•½<br><br>## ì£¼ìš” ë‚´ìš©<br><br>â€¢ **ì¬ë¬´ ì„±ê³¼ ë° ì„±ì¥ ì „ë§**: íšŒì‚¬ëŠ” ì§€ì†ì ì¸ ë§¤ì¶œ ì„±ì¥ì„¸ë¥¼ ë³´ì´ê³  ìˆìœ¼ë©°, íŠ¹íˆ ìœ ë°© ì„í”Œë€íŠ¸ ë° ë¯¸ìš© ì‹œìˆ  ì œí’ˆ ë¶€ë¬¸ì—ì„œ ê°•ë ¥í•œ ìˆ˜ìš”ë¥¼ ê²½í—˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê²½ì˜ì§„ì€ ì‹œì¥ ì ìœ ìœ¨ í™•ëŒ€ì™€ ì‹ ê·œ ì§€ì—­ ì§„ì¶œì„ í†µí•œ ì„±ì¥ ê°€ì†í™” ê°€ëŠ¥ì„±ì„ ì‹œì‚¬í–ˆìŠµë‹ˆë‹¤.<br><br>â€¢ **ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ ë° í˜ì‹ **: Motiva ì„í”Œë€íŠ¸ë¥¼ ì¤‘ì‹¬ìœ¼ë¡œ í•œ ì°¨ë³„í™”ëœ ì œí’ˆ ë¼ì¸ì—…ì´ ê²½ìŸ ìš°ìœ„ë¥¼ ì œê³µí•˜ê³  ìˆìœ¼ë©°, ê¸°ìˆ  í˜ì‹ ê³¼ ì•ˆì „ì„± í”„ë¡œí•„ì´ ì‹œì¥ì—ì„œ ê¸ì •ì ì¸ ë°˜ì‘ì„ ì–»ê³  ìˆìŠµë‹ˆë‹¤. ì¶”ê°€ì ì¸ ì œí’ˆ íŒŒì´í”„ë¼ì¸ ê°œë°œë„ ì§„í–‰ ì¤‘ì…ë‹ˆë‹¤.<br><br>â€¢ **ì§€ì—­ë³„ ì‹œì¥ ë™í–¥**: ë¼í‹´ì•„ë©”ë¦¬ì¹´ì™€ ìœ ëŸ½ì—ì„œì˜ ê²¬ê³ í•œ ì„±ê³¼ë¥¼ ë°”íƒ•ìœ¼ë¡œ, ì•„ì‹œì•„ ë° ê¸°íƒ€ ì‹ í¥ ì‹œì¥ìœ¼ë¡œì˜ í™•ì¥ì„ ì¶”ì§„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·œì œ ìŠ¹ì¸ ì§„í–‰ ìƒí™©ê³¼ ì‹œì¥ ì¹¨íˆ¬ ì „ëµì´ ì¤‘ì¥ê¸° ì„±ì¥ì˜ í•µì‹¬ ë™ë ¥ìœ¼ë¡œ ì œì‹œë˜ì—ˆìŠµë‹ˆë‹¤.<br><br>â€¢ **ê²½ì˜ì§„ í†¤**: ì „ë°˜ì ìœ¼ë¡œ ìì‹ ê° ìˆê³  ê¸ì •ì ì¸ ì–´ì¡°ë¥¼ ìœ ì§€í•˜ë©°, íšŒì‚¬ì˜ ê²½ìŸì  í¬ì§€ì…”ë‹ê³¼ ì„±ì¥ ê¶¤ë„ì— ëŒ€í•œ í™•ì‹ </p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Recon.: Raj Denhoy: I think importantly, I'll just add to that that what we will submit to the FDA by the end of this year is part of the original PMA we've already had approved. It was when we ran that study, we bifurcated the clinical piece into the augmentation cohort and then the reconstruction cohort. What the FDA needs to review now is that patient set. They don't need to re-review manufacturing. They don't have to re-review the implant. It is part of the original PMA. It's difficult, as Peter noted, to predict how long the FDA is going to take, but it shouldn't be considered a full PMA review that they need to do. Matt Taylor: Gotcha. They are open now, I think. Good news. I wanted to go back to maybe talking a little bit more about China. That was another big opportunity that you have outlined in the past, but it has been a little slow to start. Some of that, I think, is macro and working with your partner. Where are we now in China? Peter Caldini: Sure. Matt Taylor: How could that contribute next year, and do you expect to build on that in the future? Peter Caldini: Yeah, so I think, you know, as you highlighted, the macro environment in China is quite challenging. I think overall, when we look at our OUS markets, we do see stability across most of the markets. You know, I think China is probably the one exception from, you know, a macro standpoint that is impacting, you know, specifically breast augmentation. You know, in terms of the other piece of that is also building out the capabilities of our distributor. You know, we highlighted that that process has been, you know, a little bit slower than we would have expected. We've put a lot of resources and a lot of effort in terms of building out those capabilities. You know, we look at the last quarter, we've seen some good progress in terms of building out the capabilities, in terms of, you know, looking at the sellout. Peter Caldini: You know, we're very confident that China will reach the same, you know, level of market share that we have throughout Asia. I believe it will be contributing next year in terms of revenue. I think we're going in the right direction. I think also what is challenging for us, even when we build out the capabilities, the market is a little bit challenging right now. Matt Taylor: Gotcha. The other thing that we've seen internationally in the past is there's been some areas where you've gained a lot of market share and you've actually seen the bigger competitors pull back, pull out of the markets, retract. Are you continuing to see that, and could we see that happen ultimately in the U.S. or China, for example? Peter Caldini: Yeah, I think when you, you know, it's kind of hard to predict what the competitors are going to do. But, you know, when you look at, let's say, the two largest competitors in the U.S., when it's Allergan or AbbVie and J&J, and you look at their portfolio, I mean, these are not, you know, segments that are priorities for them. And, you know, as we continue to drive growth in the U.S., continue to gain share, you know, I think it makes that business for them less relevant and less of a necessity to maintain. I think there's always that potential. You know, we're going to continue to drive growth in the U.S., and I think by doing that, it's going to put pressure, and they're going to have to make those strategic decisions.</td><td>**Recon.:** ì¤‘ìš”í•œ ì ì€, ì˜¬í•´ ë§ê¹Œì§€ FDAì— ì œì¶œí•  ë‚´ìš©ì´ ì´ë¯¸ ìŠ¹ì¸ë°›ì€ ê¸°ì¡´ PMAì˜ ì¼ë¶€ë¼ëŠ” ê²ƒì…ë‹ˆë‹¤. ë‹¹ì‹œ ì„ìƒì‹œí—˜ì„ ì§„í–‰í•  ë•Œ ì„ìƒ ë¶€ë¶„ì„ í™•ëŒ€(augmentation) ì½”í˜¸íŠ¸ì™€ ì¬ê±´(reconstruction) ì½”í˜¸íŠ¸ë¡œ ë‚˜ëˆ„ì–´ ì§„í–‰í–ˆìŠµë‹ˆë‹¤. ì´ì œ FDAê°€ ê²€í† í•´ì•¼ í•  ê²ƒì€ í•´ë‹¹ í™˜ìêµ° ë°ì´í„°ì…ë‹ˆë‹¤. ì œì¡° ê³µì •ì„ ì¬ê²€í† í•  í•„ìš”ë„ ì—†ê³ , ì„í”Œë€íŠ¸ ìì²´ë¥¼ ì¬ê²€í† í•  í•„ìš”ë„ ì—†ìŠµë‹ˆë‹¤. ì´ëŠ” ì›ë˜ PMAì˜ ì¼ë¶€ì…ë‹ˆë‹¤. Peterê°€ ì–¸ê¸‰í–ˆë“¯ì´ FDAê°€ ì–¼ë§ˆë‚˜ ì‹œê°„ì„ ì†Œìš”í• ì§€ ì˜ˆì¸¡í•˜ê¸°ëŠ” ì–´ë µì§€ë§Œ, ì´ê²ƒì„ ì „ë©´ì ì¸ PMA ì¬ì‹¬ì‚¬ë¡œ ê°„ì£¼í•´ì„œëŠ” ì•ˆ ë©ë‹ˆë‹¤.<br><br>ì•Œê² ìŠµë‹ˆë‹¤. ì§€ê¸ˆì€ ì˜ì—…ì„ ì¬ê°œí•œ ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ì¢‹ì€ ì†Œì‹ì´ë„¤ìš”. ì¤‘êµ­ì— ëŒ€í•´ ì¢€ ë” ì´ì•¼ê¸°í•´ë³´ê³  ì‹¶ìŠµë‹ˆë‹¤. ì¤‘êµ­ì€ ê³¼ê±°ì— ë§ì”€ë“œë ¸ë˜ ë˜ ë‹¤ë¥¸ í° ê¸°íšŒì˜€ì§€ë§Œ, ì‹œì‘ì´ ë‹¤ì†Œ ë”ë”˜ í¸ì´ì—ˆìŠµë‹ˆë‹¤. ì¼ë¶€ëŠ” ê±°ì‹œê²½ì œ ìƒí™©ê³¼ íŒŒíŠ¸ë„ˆì‚¬ì™€ì˜ í˜‘ë ¥ ë¬¸ì œì˜€ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. í˜„ì¬ ì¤‘êµ­ ìƒí™©ì€ ì–´ë–¤ê°€ìš”? ë‚´ë…„ì— ì–´ë–¤ ê¸°ì—¬ë¥¼ í•  ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  í–¥í›„ ì´ë¥¼ ë°œì „ì‹œí‚¬ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì‹œë‚˜ìš”?<br><br>ë„¤, ë§ì”€í•˜ì‹  ëŒ€ë¡œ ì¤‘êµ­ì˜ ê±°ì‹œê²½ì œ í™˜ê²½ì€ ìƒë‹¹íˆ ì–´ë ¤ìš´ ìƒí™©ì…ë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ë¯¸êµ­ ì™¸ ì‹œì¥(OUS)ì„ ë³´ë©´ ëŒ€ë¶€ë¶„ì˜ ì‹œì¥ì—ì„œ ì•ˆì •ì„¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì¤‘êµ­ì€ ê±°ì‹œê²½ì œ ê´€ì ì—ì„œ ì˜ˆì™¸ì ì¸ ê²½ìš°ë¼ê³  í•  ìˆ˜ ìˆëŠ”ë°, íŠ¹íˆ ìœ ë°©í™•ëŒ€ìˆ  ë¶€ë¬¸ì— ì˜í–¥ì„ ë¯¸ì¹˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜ ë‹¤ë¥¸ ì¸¡ë©´ìœ¼ë¡œëŠ” ìœ í†µì—…ì²´ì˜ ì—­ëŸ‰ì„ êµ¬ì¶•í•˜ëŠ” ë¶€ë¶„ë„ ìˆìŠµë‹ˆë‹¤. ì•Œë‹¤ì‹œí”¼, ì €í¬ëŠ” ê·¸ ê³¼ì •ì´ ì˜ˆìƒë³´ë‹¤ ë‹¤ì†Œ ë”ë””ê²Œ ì§„í–‰ë˜ê³  ìˆë‹¤ëŠ” ì ì„ ì–¸ê¸‰í•œ ë°” ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” í•´ë‹¹ ì—­ëŸ‰ì„ êµ¬ì¶•í•˜ëŠ” ë° ìƒë‹¹í•œ ìì›ê³¼ ë…¸ë ¥ì„ íˆ¬ì…í•´ ì™”ìŠµë‹ˆë‹¤. ì§€ë‚œ ë¶„ê¸°ë¥¼ ë³´ë©´, ì—­ëŸ‰ êµ¬ì¶• ì¸¡ë©´ì—ì„œ, ê·¸ë¦¬ê³  íŒë§¤ ì‹¤ì  ì¸¡ë©´ì—ì„œ ìƒë‹¹í•œ ì§„ì „ì„ ë³´ì˜€ìŠµë‹ˆë‹¤.<br><br>ì €í¬ëŠ” ì¤‘êµ­ì´ ì•„ì‹œì•„ ì „ì—­ì—ì„œ ì €í¬ê°€ ë³´ìœ í•œ ê²ƒê³¼ ë™ì¼í•œ ìˆ˜ì¤€ì˜ ì‹œì¥ ì ìœ ìœ¨ì— ë„ë‹¬í•  ê²ƒì´ë¼ê³  í™•ì‹ í•©ë‹ˆë‹¤. ë‚´ë…„ì—ëŠ” ë§¤ì¶œ ê¸°ì—¬ê°€ ì´ë£¨ì–´ì§ˆ ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. ì˜¬ë°”ë¥¸ ë°©í–¥ìœ¼ë¡œ ê°€ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë˜í•œ ì €í¬ì—ê²Œ ì–´ë ¤ìš´ ì ì€, ì—­ëŸ‰ì„ êµ¬ì¶•í•˜ë”ë¼ë„ í˜„ì¬ ì‹œì¥ ìƒí™©ì´ ë‹¤ì†Œ ì–´ë µë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤.<br><br>ì•Œê² ìŠµë‹ˆë‹¤. ê³¼ê±° í•´ì™¸ ì‹œì¥ì—ì„œ ì €í¬ê°€ ìƒë‹¹í•œ ì‹œì¥ ì ìœ ìœ¨ì„ í™•ë³´í–ˆì„ ë•Œ, ì‹¤ì œë¡œ ëŒ€í˜• ê²½ìŸì‚¬ë“¤ì´ ì² ìˆ˜í•˜ê±°ë‚˜ ì‹œì¥ì—ì„œ í›„í‡´í•˜ëŠ” ëª¨ìŠµì„ ë³´ì…¨ëŠ”ë°ìš”. ì´ëŸ° í˜„ìƒì´ ê³„ì†ë˜ê³  ìˆëŠ”ì§€, ê·¸ë¦¬ê³  ê¶ê·¹ì ìœ¼ë¡œ ë¯¸êµ­ì´ë‚˜ ì¤‘êµ­ ê°™ì€ ì‹œì¥ì—ì„œë„ ì´ëŸ° ì¼ì´ ì¼ì–´ë‚  ìˆ˜ ìˆì„ê¹Œìš”?<br><br>ê²½ìŸì‚¬ë“¤ì´ ì–´ë–»ê²Œ ì›€ì§ì¼ì§€ ì˜ˆì¸¡í•˜ê¸°ëŠ” ì–´ë µìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë¯¸êµ­ì˜ ì–‘ëŒ€ ê²½ìŸì‚¬ì¸ ì•¨ëŸ¬ê°„(Allergan) ë˜ëŠ” ì• ë¸Œë¹„(AbbVie)ì™€ ì¡´ìŠ¨ì•¤ë“œì¡´ìŠ¨(J&J)ì„ ë³´ë©´, ì´ë“¤ì˜ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì‚´í´ë´¤ì„ ë•Œ ì´ ë¶„ì•¼ê°€ ê·¸ë“¤ì—ê²Œ ìš°ì„ ìˆœìœ„ ì‚¬ì—…ì€ ì•„ë‹™ë‹ˆë‹¤. ë¯¸êµ­ì—ì„œ ì§€ì†ì ìœ¼ë¡œ ì„±ì¥ì„ ì¶”ì§„í•˜ê³  ì‹œì¥ ì ìœ ìœ¨ì„ í™•ëŒ€í•´ ë‚˜ê°€ë©´ì„œ, ê·¸ë“¤ì˜ ì‚¬ì—…ì´ ì ì  ë” ê´€ë ¨ì„±ì´ ë–¨ì–´ì§€ê³  ìœ ì§€í•  í•„ìš”ì„±ë„ ì¤„ì–´ë“¤ ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. ê·¸ëŸ° ê°€ëŠ¥ì„±ì€ í•­ìƒ ì¡´ì¬í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë¯¸êµ­ì—ì„œ ê³„ì† ì„±ì¥ì„ ê²¬ì¸í•  ê²ƒì´ê³ , ê·¸ë ‡ê²Œ í•¨ìœ¼ë¡œì¨ ì••ë°•ì„ ê°€í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ê·¸ëŸ¬ë©´ ê·¸ë“¤ì€ ì „ëµì  ê²°ì •ì„ ë‚´ë ¤ì•¼ í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Doesn't make sense.: Peter Caldini: If you do look at, and having worked in a lot of these big multinationals, that's a common, you know, that's a common process. At a certain point, they're going to get to the level where it doesn't make sense to maintain the business. When that happens, I don't know, but, you know, I think that could be a reality. Matt Taylor: I guess going back to international, you know, I think with the success you've had so far in the U.S., you've convinced a lot of investors that you're going to be a big player there. What about your ability to continue to drive growth in international, broadly speaking, where there has also been sort of a tough macro environment for a few years? Peter Caldini: Yeah, I think overall, I think the macro environment has been stable, as I mentioned. I think there are certain areas where you have good growth from a market standpoint, but there are some challenges. We highlighted China. You know, for us, we're very pleased with the progress we made this year in our OUS markets. We made a strategic decision to really focus on the direct markets. You know, these are markets, these are the larger markets. You know, when you talk about Western Europe, we have much better revenue potential. You know, we've dedicated a lot of resources, and we reallocate a lot of our resources from distributor markets to direct markets to really take advantage of the opportunities. In these markets, we have much better economics. You know, we've seen a lot of success. You know, I mentioned before the growth rates in Western Europe, 20% growth. Peter Caldini: You know, we're stealing share in a lot of these markets. We've been adding a number of accounts in Western Europe. We've added about 10% across all our direct markets. Preserve and the minimally invasive platform is really helping drive a lot of that growth. You know, for me, that's going to be, you know, a key growth driver for us. It's going to help drive the profitability as well. You know, I think we've made a lot of good traction so far, and that's going to continue in Q4 all the way through 2026 and beyond. Matt Taylor: Maybe we'll end on a few questions on the pipeline. You've always described yourselves as a women's health company. I think a lot of investors don't even know about JEM. Maybe we could start by talking about the JEM program, you know, where that is and what kind of an opportunity that could be in the future. Peter Caldini: Yeah, you know, I think we don't talk about it a lot because we have so much close in. You know, when I think you look at the breast augmentation, the Recon Indication in the U.S., I think for JEM, that's a later down pipeline opportunity. I think it could be a very sizable opportunity. We're going to be first looking at launching that in Latin America, probably around late 2026, 2027. A lot of this is going to be dependent on the regulatory pathways in the U.S. and also in Europe. I think in Latin America, it's going to be a little bit easier. I think that's going to be really after really leveraging and utilizing the opportunities we have in terms of the breast augmentation space. That's going to be something that's going to really fuel the growth in 2028 and beyond. Matt Taylor: Could you describe what JEM is, the value proposition and the unmet need it addresses? Raj Denhoy: Yeah, so it's in the gluteal augmentation space, right, which is a market that is sizable and has grown over the last few years. The, you know, currently available technologies there are pretty substandard. There's not been much innovation at all. Frankly, some of the injections and fillers that are used can be quite dangerous. We are taking some of the core technologies we have in our minimally invasive portfolio, the injection device, the implants, and really adapting them to use in a gluteal augmentation approach. As Peter noted, it's still in clinicals, and we're still working through this. For what we've seen, it's very encouraging. It is really a pipeline product to really think about it contributing, as Peter noted, in 2027 and beyond. The opportunity is there. Raj Denhoy: We believe we have something that's pretty unique and differentiated, and you'll hear more from us over the next couple of years on it. Matt Taylor: Maybe I'll end on a fun one. You're very popular on Instagram. Raj Denhoy: Meet Raj? Peter Caldini: Yeah. Matt Taylor: The company. You have also had, you know, some signups of brand ambassadors and are doing some marketing that way. Maybe just talk a little bit about that strategy to get recognition of the brand and kind of the buzz that is being created by some of the online marketing. Peter Caldini: Yeah, I think, you know, especially you see this in the U.S. I mean, we did the Meghan Trainor campaign. That's been tremendously successful for us, not only to create the interest. We've been able to track the number of patients that have come in specifically on that program. Also, I think we've just overall been able to create a lot of buzz in the industry. Some of that is driven by us, and a lot of it's driven also by the surgeons. You know, I think in some respects, there really hasn't been, you know, a lot of innovation coming to the market in the U.S. I think once we came in and we provided a lot of materials, I think, you know, along with the things that we're doing, the surgeons are also very excited about it. Peter Caldini: You see them doing a lot of posting and reposting. I think that's really been able to drive a lot of the growth. I think for us, it's very unusual that you have patients walking in, talking to surgeons, and asking specifically for Motiva. You know, we're very proud about the efforts. That really helps us to drive the penetration and the utilization rates. That's going to continue into 2026 and beyond. Matt Taylor: Great. I'll be waiting for my contract. Peter Caldini: I'm not sure you're the right target, though. Matt Taylor: All right. Thank you guys for your time, and thanks everybody for your interest in this action. Peter Caldini: Thank you. Raj Denhoy: Thank you.</td><td>**Doesn't make sense.:** ë§ì€ ë‹¤êµ­ì  ê¸°ì—…ë“¤ì—ì„œ ì¼í•´ë³¸ ê²½í—˜ìœ¼ë¡œ ë³¼ ë•Œ, ì´ê±´ í”í•œ í”„ë¡œì„¸ìŠ¤ì…ë‹ˆë‹¤. ì–´ëŠ ì‹œì ì´ ë˜ë©´ ì‚¬ì—…ì„ ìœ ì§€í•˜ëŠ” ê²ƒì´ ë” ì´ìƒ ì˜ë¯¸ê°€ ì—†ëŠ” ìˆ˜ì¤€ì— ë„ë‹¬í•˜ê²Œ ë©ë‹ˆë‹¤. ê·¸ê²Œ ì–¸ì œê°€ ë ì§€ëŠ” ëª¨ë¥´ê² ì§€ë§Œ, ì¶©ë¶„íˆ í˜„ì‹¤í™”ë  ìˆ˜ ìˆëŠ” ì‹œë‚˜ë¦¬ì˜¤ë¼ê³  ë´…ë‹ˆë‹¤.<br><br>êµ­ì œ ì‚¬ì—…ìœ¼ë¡œ ë‹¤ì‹œ ëŒì•„ê°€ì„œ ë§ì”€ë“œë¦¬ë©´, ì§€ê¸ˆê¹Œì§€ ë¯¸êµ­ì—ì„œ ê±°ë‘” ì„±ê³¼ë¡œ ë§ì€ íˆ¬ììë“¤ê»˜ ìš°ë¦¬ê°€ ê·¸ ì‹œì¥ì—ì„œ ì£¼ìš” í”Œë ˆì´ì–´ê°€ ë  ê²ƒì´ë¼ëŠ” í™•ì‹ ì„ ë“œë¦° ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ êµ­ì œ ì‹œì¥ì—ì„œì˜ ì§€ì†ì ì¸ ì„±ì¥ ë™ë ¥ì€ ì–´ë–»ê²Œ ë³´ì‹œëŠ”ì§€ìš”? íŠ¹íˆ ì§€ë‚œ ëª‡ ë…„ê°„ ê±°ì‹œê²½ì œ í™˜ê²½ì´ ì¢‹ì§€ ì•Šì•˜ë˜ ì ì„ ê°ì•ˆí•˜ë©´ ë§ì…ë‹ˆë‹¤.<br><br>ì „ë°˜ì ìœ¼ë¡œ ë³´ë©´ ê±°ì‹œê²½ì œ í™˜ê²½ì€ ì œê°€ ì•ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ì•ˆì •ì ì´ì—ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì‹œì¥ ê´€ì ì—ì„œ ë³´ë©´ ì¢‹ì€ ì„±ì¥ì„ ë³´ì´ëŠ” ì˜ì—­ë“¤ì´ ìˆì§€ë§Œ, ë™ì‹œì— ëª‡ ê°€ì§€ ì–´ë ¤ì›€ë„ ìˆìŠµë‹ˆë‹¤. ì¤‘êµ­ ì‹œì¥ì„ ì–¸ê¸‰í–ˆì—ˆì£ . ì €í¬ë¡œì„œëŠ” ì˜¬í•´ í•´ì™¸ ì‹œì¥ì—ì„œ ì´ë£¬ ì§„ì „ì— ë§¤ìš° ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì§ì ‘ ì‹œì¥ì— ì§‘ì¤‘í•˜ê¸°ë¡œ ì „ëµì  ê²°ì •ì„ ë‚´ë ¸ìŠµë‹ˆë‹¤. ì´ëŸ° ì‹œì¥ë“¤ì€ ê·œëª¨ê°€ í° ì‹œì¥ë“¤ì´ì£ . ì„œìœ ëŸ½ì„ ì˜ˆë¡œ ë“¤ë©´, í›¨ì”¬ ë” ë‚˜ì€ ë§¤ì¶œ ì ì¬ë ¥ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ë§ì€ ìì›ì„ íˆ¬ì…í–ˆê³ , ì‹¤ì œë¡œ ìœ í†µì—…ì²´ ì‹œì¥ì—ì„œ ì§ì ‘ ì‹œì¥ìœ¼ë¡œ ìì›ì„ ëŒ€ê±° ì¬ë°°ì¹˜í•´ì„œ ê¸°íšŒë¥¼ ì œëŒ€ë¡œ í™œìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ° ì‹œì¥ë“¤ì—ì„œëŠ” ê²½ì œì„±ì´ í›¨ì”¬ ë” ì¢‹ìŠµë‹ˆë‹¤. ë§ì€ ì„±ê³¼ë¥¼ ê±°ë‘ê³  ìˆê³ ìš”. ì•ì„œ ë§ì”€ë“œë ¸ë“¯ì´ ì„œìœ ëŸ½ì—ì„œ 20% ì„±ì¥ë¥ ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ë§ì€ ì‹œì¥ì—ì„œ ì ìœ ìœ¨ì„ í™•ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì„œìœ ëŸ½ì—ì„œ ë‹¤ìˆ˜ì˜ ê±°ë˜ì²˜ë¥¼ ì¶”ê°€í–ˆê³ , ëª¨ë“  ì§ì ‘ ì‹œì¥ì—ì„œ ì•½ 10% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. Preserveì™€ ìµœì†Œì¹¨ìŠµ í”Œë«í¼ì´ ì´ëŸ¬í•œ ì„±ì¥ì˜ ë§ì€ ë¶€ë¶„ì„ ê²¬ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì œê°€ ë³´ê¸°ì— ì´ê²ƒì´ ì €í¬ì˜ í•µì‹¬ ì„±ì¥ ë™ë ¥ì´ ë  ê²ƒì´ë©°, ìˆ˜ìµì„± í–¥ìƒì—ë„ ê¸°ì—¬í•  ê²ƒì…ë‹ˆë‹¤. ì§€ê¸ˆê¹Œì§€ ìƒë‹¹í•œ ì§„ì „ì„ ì´ë£¨ì—ˆë‹¤ê³  ìƒê°í•˜ë©°, ì´ëŠ” 4ë¶„ê¸°ë¥¼ ê±°ì³ 2026ë…„ê³¼ ê·¸ ì´í›„ê¹Œì§€ ê³„ì†ë  ê²ƒì…ë‹ˆë‹¤.<br><br>íŒŒì´í”„ë¼ì¸ì— ëŒ€í•œ ëª‡ ê°€ì§€ ì§ˆë¬¸ìœ¼ë¡œ ë§ˆë¬´ë¦¬í•˜ê² ìŠµë‹ˆë‹¤. ê·€ì‚¬ëŠ” í•­ìƒ ìŠ¤ìŠ¤ë¡œë¥¼ ì—¬ì„± ê±´ê°• íšŒì‚¬ë¡œ ì„¤ëª…í•´ ì™”ìŠµë‹ˆë‹¤. ë§ì€ íˆ¬ììë“¤ì´ JEMì— ëŒ€í•´ì„œëŠ” ì˜ ëª¨ë¥´ê³  ìˆëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤. JEM í”„ë¡œê·¸ë¨ì— ëŒ€í•´ ë¨¼ì € ë§ì”€ë“œë¦¬ìë©´, í˜„ì¬ ì§„í–‰ ìƒí™©ê³¼ í–¥í›„ ê¸°íšŒì— ëŒ€í•´ì„œ ë§ì´ì£ . ì‚¬ì‹¤ ì €í¬ê°€ ì´ í”„ë¡œê·¸ë¨ì— ëŒ€í•´ ë§ì´ ì–¸ê¸‰í•˜ì§€ ì•ŠëŠ” ì´ìœ ëŠ” ë‹¹ì¥ ëˆˆì•ì— ì§‘ì¤‘í•´ì•¼ í•  ê²ƒë“¤ì´ ë„ˆë¬´ ë§ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ìœ ë°© í™•ëŒ€ìˆ ì´ë‚˜ ë¯¸êµ­ ë‚´ ì¬ê±´ ì ì‘ì¦ì„ ë³´ì‹œë©´, JEMì˜ ê²½ìš° íŒŒì´í”„ë¼ì¸ ìƒ ì¢€ ë” í›„ë°˜ë¶€ì— ìˆëŠ” ê¸°íšŒë¼ê³  í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ ì´ê²ƒì€ ìƒë‹¹íˆ í° ê·œëª¨ì˜ ê¸°íšŒê°€ ë  ìˆ˜ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. ìš°ì„ ì€ ë¼í‹´ì•„ë©”ë¦¬ì¹´ì—ì„œ ë¨¼ì € ì¶œì‹œí•  ê³„íšì´ê³ , ì‹œê¸°ëŠ” ì•„ë§ˆ 2026ë…„ ë§ì—ì„œ 2027ë…„ ì •ë„ê°€ ë  ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒì€ ë¯¸êµ­ê³¼ ìœ ëŸ½ì˜ ê·œì œ ê²½ë¡œì— ë”°ë¼ ë‹¬ë¼ì§ˆ ê²ƒì…ë‹ˆë‹¤. ë¼í‹´ì•„ë©”ë¦¬ì¹´ì˜ ê²½ìš° ê·œì œ ì¸¡ë©´ì—ì„œ ì¢€ ë” ìˆ˜ì›”í•  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ìœ ë°© í™•ëŒ€(breast augmentation) ë¶„ì•¼ì—ì„œ ìš°ë¦¬ê°€ ê°€ì§„ ê¸°íšŒë“¤ì„ ì¶©ë¶„íˆ í™œìš©í•œ ì´í›„ì— ë‚˜ì˜¬ ê²ƒì…ë‹ˆë‹¤. ì´ê²ƒì´ 2028ë…„ ì´í›„ ì„±ì¥ì„ ì‹¤ì§ˆì ìœ¼ë¡œ ê²¬ì¸í•  ìš”ì†Œê°€ ë  ê²ƒì…ë‹ˆë‹¤.<br><br>Matt Taylor: JEMì´ ë¬´ì—‡ì¸ì§€, ê·¸ ê°€ì¹˜ ì œì•ˆê³¼ í•´ê²°í•˜ê³ ì í•˜ëŠ” ë¯¸ì¶©ì¡± ìˆ˜ìš”ì— ëŒ€í•´ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?<br><br>ë„¤, ë‘”ë¶€ í™•ëŒ€(gluteal augmentation) ë¶„ì•¼ì˜ ì œí’ˆì…ë‹ˆë‹¤. ì´ëŠ” ìƒë‹¹í•œ ê·œëª¨ì˜ ì‹œì¥ì´ë©° ì§€ë‚œ ëª‡ ë…„ê°„ ì„±ì¥í•´ ì™”ìŠµë‹ˆë‹¤. í˜„ì¬ ì´ìš© ê°€ëŠ¥í•œ ê¸°ìˆ ë“¤ì€ ìƒë‹¹íˆ ìˆ˜ì¤€ ì´í•˜ì…ë‹ˆë‹¤. í˜ì‹ ì´ ê±°ì˜ ì—†ì—ˆë‹¤ê³  ë´ì•¼ í•©ë‹ˆë‹¤. ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´, í˜„ì¬ ì‚¬ìš©ë˜ëŠ” ì¼ë¶€ ì£¼ì‚¬ì œë‚˜ í•„ëŸ¬(filler)ëŠ” ìƒë‹¹íˆ ìœ„í—˜í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ìµœì†Œ ì¹¨ìŠµ í¬íŠ¸í´ë¦¬ì˜¤ì˜ í•µì‹¬ ê¸°ìˆ ë“¤, ì¦‰ ì£¼ì… ì¥ì¹˜ì™€ ì„í”Œë€íŠ¸ë¥¼ ë‘”ë¶€ í™•ëŒ€ìˆ (gluteal augmentation)ì— ì ìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤. Peterê°€ ì–¸ê¸‰í–ˆë“¯ì´, ì•„ì§ ì„ìƒ ë‹¨ê³„ì— ìˆê³  ê³„ì† ê°œë°œ ì¤‘ì…ë‹ˆë‹¤. ì§€ê¸ˆê¹Œì§€ ë³¸ ê²°ê³¼ëŠ” ë§¤ìš° ê³ ë¬´ì ì…ë‹ˆë‹¤. ì´ê²ƒì€ íŒŒì´í”„ë¼ì¸ ì œí’ˆìœ¼ë¡œ, Peterê°€ ë§í•œ ëŒ€ë¡œ 2027ë…„ ì´í›„ì— ì‹¤ì§ˆì ì¸ ê¸°ì—¬ë¥¼ í•  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ê¸°íšŒëŠ” ì¶©ë¶„íˆ ìˆìŠµë‹ˆë‹¤.<br><br>ì €í¬ëŠ” ìƒë‹¹íˆ ë…íŠ¹í•˜ê³  ì°¨ë³„í™”ëœ ì œí’ˆì„ ë³´ìœ í•˜ê³  ìˆë‹¤ê³  ë¯¿ìœ¼ë©°, ì•ìœ¼ë¡œ ëª‡ ë…„ê°„ ë” ë§ì€ ì†Œì‹ì„ ì „í•´ë“œë¦¬ê² ìŠµë‹ˆë‹¤.<br><br>ì¬ë¯¸ìˆëŠ” ì§ˆë¬¸ìœ¼ë¡œ ë§ˆë¬´ë¦¬í•˜ì‹œë„¤ìš”. ì¸ìŠ¤íƒ€ê·¸ë¨ì—ì„œ ì¸ê¸°ê°€ ë§ìœ¼ì‹œë˜ë°ìš”.<br><br>Rajë¥¼ ë§Œë‚˜ë³´ì‹¤ë˜ìš”?<br><br>ë„¤.<br><br>íšŒì‚¬ ë§ì”€ì´ì‹œì£ . ë¸Œëœë“œ ì•°ë°°ì„œë” ê³„ì•½ì„ ì²´ê²°í•˜ê³  ê·¸ ë°©ì‹ìœ¼ë¡œ ë§ˆì¼€íŒ…ì„ ì§„í–‰í•˜ê³  ê³„ì‹ ë°ìš”. ë¸Œëœë“œ ì¸ì§€ë„ë¥¼ ë†’ì´ê¸° ìœ„í•œ ì „ëµê³¼ ì˜¨ë¼ì¸ ë§ˆì¼€íŒ…ì„ í†µí•´ ë§Œë“¤ì–´ì§€ê³  ìˆëŠ” í™”ì œì„±ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?<br><br>íŠ¹íˆ ë¯¸êµ­ ì‹œì¥ì—ì„œ ì´ëŸ° íš¨ê³¼ë¥¼ í™•ì¸í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë©”ê±´ íŠ¸ë ˆì´ë„ˆ(Meghan Trainor) ìº í˜ì¸ì„ ì§„í–‰í–ˆëŠ”ë°, ê´€ì‹¬ì„ ëŒì–´ë‚´ëŠ” ê²ƒì€ ë¬¼ë¡ ì´ê³  í•´ë‹¹ í”„ë¡œê·¸ë¨ì„ í†µí•´ ìœ ì…ëœ í™˜ì ìˆ˜ë¥¼ ì¶”ì í•  ìˆ˜ ìˆì—ˆë‹¤ëŠ” ì ì—ì„œ ì—„ì²­ë‚œ ì„±ê³µì„ ê±°ë’€ìŠµë‹ˆë‹¤. ë˜í•œ ì „ë°˜ì ìœ¼ë¡œ ì—…ê³„ ë‚´ì—ì„œ ë§ì€ í™”ì œë¥¼ ë§Œë“¤ì–´ë‚¼ ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ í™”ì œëŠ” ì¼ë¶€ëŠ” ì €í¬ê°€ ì£¼ë„í•œ ê²ƒì´ê³ , ìƒë‹¹ ë¶€ë¶„ì€ ì§‘ë„ì˜ë“¤ì— ì˜í•´ì„œë„ ë§Œë“¤ì–´ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì–´ë–¤ ë©´ì—ì„œ ë³´ë©´ ë¯¸êµ­ ì‹œì¥ì— ì‹¤ì§ˆì ìœ¼ë¡œ ë§ì€ í˜ì‹ ì´ ë‚˜ì˜¤ì§€ ì•Šì•˜ë˜ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì €í¬ê°€ ì§„ì…í•´ì„œ ë‹¤ì–‘í•œ ì œí’ˆë“¤ì„ ì œê³µí•˜ë©´ì„œ, ì €í¬ê°€ í•˜ê³  ìˆëŠ” ì¼ë“¤ê³¼ í•¨ê»˜ ì™¸ê³¼ì˜ì‚¬ë“¤ë„ ë§¤ìš° í¥ë¯¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì™¸ê³¼ì˜ì‚¬ë“¤ì´ ë§ì€ ê²Œì‹œë¬¼ì„ ì˜¬ë¦¬ê³  ì¬ê³µìœ í•˜ëŠ” ê²ƒì„ ë³¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì •ë§ë¡œ ë§ì€ ì„±ì¥ì„ ê²¬ì¸í•  ìˆ˜ ìˆì—ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì €í¬ì—ê²ŒëŠ” í™˜ìë“¤ì´ ì§ì ‘ ì°¾ì•„ì™€ì„œ ì™¸ê³¼ì˜ì‚¬ì™€ ìƒë‹´í•˜ë©´ì„œ êµ¬ì²´ì ìœ¼ë¡œ ëª¨í‹°ë°”ë¥¼ ìš”ì²­í•˜ëŠ” ê²ƒì´ ë§¤ìš° ì´ë¡€ì ì¸ ì¼ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ë…¸ë ¥ì— ëŒ€í•´ ë§¤ìš° ìë¶€ì‹¬ì„ ëŠë¼ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì‹¤ì œë¡œ ì‹œì¥ ì¹¨íˆ¬ìœ¨ê³¼ í™œìš©ë¥ ì„ ë†’ì´ëŠ” ë° ë„ì›€ì´ ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” 2026ë…„ê³¼ ê·¸ ì´í›„ì—ë„ ê³„ì†ë  ê²ƒì…ë‹ˆë‹¤.<br><br>ì¢‹ìŠµë‹ˆë‹¤. ì œ ê³„ì•½ì„œë¥¼ ê¸°ë‹¤ë¦¬ê³  ìˆê² ìŠµë‹ˆë‹¤. ë‹¹ì‹ ì´ ì ì ˆí•œ ëŒ€ìƒì¸ì§€ëŠ” ì˜ ëª¨ë¥´ê² ë„¤ìš”.<br><br>ì•Œê² ìŠµë‹ˆë‹¤. ì‹œê°„ ë‚´ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ë²ˆ ê±´ì— ê´€ì‹¬ ê°€ì ¸ì£¼ì‹  ëª¨ë“  ë¶„ë“¤ê»˜ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤.<br><br>ê°ì‚¬í•©ë‹ˆë‹¤.<br><br>ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Establishment Labs ì‹¤ì  ë°œí‘œ ìš”ì•½<br><br>## ì£¼ìš” ë‚´ìš©<br><br>â€¢ **ë¯¸êµ­ ì‹œì¥ ì§„ì¶œ ì„±ê³µ**: FDA ìŠ¹ì¸ í›„ ì²« í•´ì— 1,300ê°œ ê³„ì • í™•ë³´, ì—°ë§ ì‹œì¥ì ìœ ìœ¨ 20% ë‹¬ì„± ì „ë§. ê²½ìŸì‚¬ ëŒ€ë¹„ ìš°ìˆ˜í•œ ì•ˆì „ì„± í”„ë¡œíŒŒì¼(ê¸°ê¸° ê´€ë ¨ í•©ë³‘ì¦ 1% ë¯¸ë§Œ)ê³¼ í˜ì‹ ì  ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ê¸°ë°˜ìœ¼ë¡œ ë¹ ë¥¸ ì‹œì¥ ì¹¨íˆ¬ ë‹¬ì„±. 2026ë…„ ìµœëŒ€ 15ëª…ì˜ ì˜ì—… ì¸ë ¥ ì¶”ê°€ íˆ¬ì ê³„íš<br><br>â€¢ **ìˆ˜ìµì„± ê°œì„  ë° ì¬ë¬´ ëª©í‘œ**: EBITDA í‘ì ì „í™˜ ë‹¬ì„±, 2026ë…„ í˜„ê¸ˆíë¦„ í‘ì ëª©í‘œ ì„¤ì •. ë¯¸êµ­ ì‹œì¥ì˜ ë†’ì€ ê°€ê²© ì‹¤í˜„(ê¸€ë¡œë²Œ í‰ê·  ëŒ€ë¹„ 2ë°° ì´ìƒ)ìœ¼ë¡œ ë§¤ì¶œì´ì´ìµë¥  70% ëŒíŒŒ. ì œì¡° ì¸í”„ë¼ íˆ¬ì ì™„ë£Œë¡œ í–¥í›„ ì¦ë¶„ ë§¤ì¶œì˜ ëŒ€ë¶€ë¶„ì´ ì´ìµìœ¼ë¡œ ì „í™˜ë  ì „ë§<br><br>â€¢ **ì œí’ˆ íŒŒì´í”„ë¼ì¸ í™•ëŒ€**: 2026ë…„ 1ë¶„ê¸° ìµœì†Œì¹¨ìŠµ í¬íŠ¸í´ë¦¬ì˜¤(PreservÃ©) ë¯¸êµ­ ì¶œì‹œ ì˜ˆì •, ì—°ë§ ì¬ê±´(Recon) ì ì‘ì¦ PMA ì œì¶œ ê³„íš. ìµœì†Œì¹¨ìŠµ ì œí’ˆêµ°(Mia + PreservÃ©)ì€ 2025ë…„ $30M ì´ìƒ ë§¤ì¶œ ëª©í‘œ. ìœ ëŸ½ ì§ì ‘ ì‹œì¥ì—ì„œ 20% ì´ìƒ ì„±ì¥í•˜ë©° í˜ì‹  ì œí’ˆì˜ ì‹œì¥ í™•ëŒ€ íš¨ê³¼ ì…ì¦<br><br>â€¢ **ê²½ì˜ì§„ í†¤**: ë§¤ìš° ê¸ì •ì ì´</p>
    <hr style="margin:50px 0;">
    
</body></html>